Second Genome has dosed first patient in a Phase 2 test of its oral, small molecule inhibitor of P2X7, called SGM-1019, for treating nonalcoholic steatohepatitis (NASH), expecting topline date in 2020.
A receptor that is involved in inflammasome activation and mediates inflammation and fibrosis.
Stephen Harrison, Medical Director of Pinnacle Clinical Research and the study’s Principal Investigator, noted that there are no approved therapies for NASH at this time, and, while there are many in development, SGM-1019 is directed at the inflammation underlying this condition.
“We know that inhibiting P2X7 results in significant reduction in inflammation and fibrosis in preclinical models of disease and look forward to seeing the data from this study. SGM-1019 has the potential to provide a much needed treatment option for the growing number of patients with NASH.”
Karim Dabbagh, president and CEO of Second Genome, sees 2019 as a defining year for Second Genome, with the team, platform, pipeline and vision in place to truly make a difference in the lives of patients.
He added that the company also expects earlier programs to deliver clinical candidate molecules and early leads in its core indications.